Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Target CD7 CAR-T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
T-cell Acute Lymphoblastic Leukemia
1 trial -
Tetrahydrobiopterin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Radiation-Induced Dermatitis
1 trial -
The 10mg dose group
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Healthy Volunteers
1 trial -
ThisCART19A
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Autoimmune Hemolytic Anemia
1 trial -
ThisCART19A
The First People's Hospital of Lianyungang
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
1 trial -
ThisCART19A with Dose Level 1
The First People's Hospital of Lianyungang
CAR
1 trial -
ThisCART22 cells injection
The First People's Hospital of Lianyungang
B Cell Malignancy
1 trial -
ThisCART7 cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
T-Acute Lymphoblastic Leukemia
1 trial -
Tissue Plasminogen Activator (tPA)
Hospital Authority, Hong Kong
Peritoneal Dialysis
1 trial -
Tofacitinib tablets
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Amyotrophic Lateral Sclerosis
1 trial -
Tranexamic AcidοΌ
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Iatrogenic Endobronchial Bleeding
1 trial -
Tranilast
The First People's Hospital of Lianyungang
Mucinoses
1 trial -
Triprorelin for injection
The First People's Hospital of Lianyungang
Prostate Cancer (CRPC)
1 trial -
U96
The First People's Hospital of Lianyungang
Relapsed or Refractory B Cell Leukemia and Lymphoma
1 trial -
UB-221
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chronic Spontaneous Urticaria
1 trial -
UB-VV410
The First People's Hospital of Lianyungang
Systemic Lupus Erythematosus
1 trial -
UCBMC
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stroke
1 trial -
UCMSC
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Bronchopleural Fistula
1 trial -
UTAA09 injection
The First People's Hospital of Lianyungang
Recurrent or Refractory B-cell Non Hodgkin's Lymphoma
1 trial -
UTAA91 injection
Hospital Authority, Hong Kong
Rheumatoid Arthritis (RA)
1 trial -
UX-GIP001
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Epilepsy
1 trial -
VGB-R04
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hemophilia B
1 trial -
Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 Β΅g
Hospital Authority, Hong Kong
COVID-19 Pandemic
1 trial -
Vemurafenib Oral Tablet [Zelboraf]
Xiyuan Hospital of China Academy of Chinese Medical Sciences
BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources